0
By providing all interested manufacturers with the same approved H1N1 MSV, APHIS will eliminate the need for each manufacturer to focus resources on developing its own master seed that would then require CVB confirmatory testing. Instead, while the "global" MSV is undergoing tests at CVB, each interested manufacturer can begin working immediately on the next steps involved in novel vaccine production. In the event that the virus appears to be an emerging disease in swine, producers will have a vaccine available much more quickly than they would under the normal production process, possibly as early as November or December 2009.
http://www.aphis.usda.gov/newsroom/content/2009/06/h1n1vac.shtml
